Skip to main content

Table 3 Pharmacokinetic parameters (mean ± SD) of laquinimod in MS patients following repeated daily administration for 21 days

From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Dose (mg) n t max a (h) C max (ng/mL) C min (ng/mL) AUC0–24 (ng h/mL) Dose -normalized
C max AUC0–24h
0.9 10 0.99 (0.25–2.00) 639.6 ± 114.9 469.5 ± 103.4 12,245.8 ± 2075.4 710.6 ± 127.6 13,606.5 ± 2306.0
1.2 12 0.75 (0.25–4.00) 779.2 ± 115.7 565.7 ± 121.0 15,075.2 ± 2757.6 649.4 ± 96.4 12,562.7 ± 2298.0
1.5 12 1.00 (0.50–24.00) 1207.8 ± 210.8 904.0 ± 189.5 22,974.0 ± 3756.6 805.2 ± 140.6 15,316.0 ± 2504.4
1.8 11 0.50 (0.25–3.00) 1449.4 ± 325.4 1076.7 ± 274.3 28,042.7 ± 6495.5 805.2 ± 180.8 15,579.3 ± 3608.6
2.1 11 2.00 (0.50–6.00) 1712.1 ± 385.8 1310.5 ± 356.0 33,741.2 ± 8133.4 815.3 ± 183.7 16,067.2 ± 3873.1
2.4 10 0.50 (0.50–2.00) 1892.3 ± 526.3 1389.3 ± 512.9 35,470.0 ± 11,100.2 788.5 ± 219.3 14,779.2 ± 4625.1
2.7 10 1.00 (0.5–2.00) 1826.2 ± 313.4 1364.5 ± 186.7 35,274.5 ± 5973.0 676.4 ± 116.1 13,064.6 ± 2212.2
  1. AUC 0–24 area under the plasma concentration-time curve from 0 to 24 h postdose, C max maximum plasma concentration, C min minimum plasma concentration, t max time to maximum plasma concentration
  2. aMedian (range) is provided for t max